View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2013	Jul. 31, 2013
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	PACB
Entity Registrant Name	PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Entity Central Index Key	0001299130
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		65,250,352

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Current assets
Cash and cash equivalents	$ 40,833	$ 46,540
Investments	66,135	54,040
Accounts receivable	4,104	2,822
Inventory, net	10,283	9,592
Prepaid expenses and other current assets	759	2,006
Total current assets	122,114	115,000
Property and equipment, net	11,655	14,329
Other long-term assets	508	354
Total assets	134,277	129,683
Current liabilities
Accounts payable	2,605	2,988
Accrued expenses and other current liabilities	8,950	8,204
Deferred revenue, current	3,347	3,378
Facility financing obligation, current	191	173
Total current liabilities	15,093	14,743
Deferred revenue, non-current	734	800
Deferred rent and other long-term liabilities	1,638	2,145
Notes payable	13,007
Financing derivative	894
Facility financing obligation, non-current	2,513	2,613
Total liabilities	33,879	20,301
Stockholders' equity
Convertible Preferred Stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding
Common Stock and additional paid-in-capital, $0.001 par value: Authorized 1,000,000 shares; Issued and outstanding 65,242 shares at June 30, 2013 and 56,170 shares at December 31, 2012	677,995	645,372
Accumulated other comprehensive income	(2)	30
Accumulated deficit	(577,595)	(536,020)
Total stockholders' equity	100,398	109,382
Total liabilities and stockholders' equity	$ 134,277	$ 129,683

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Convertible Preferred Stock, par value	$ 0.001	$ 0.001
Convertible Preferred Stock, shares authorized	50,000	50,000
Convertible Preferred Stock, shares issued
Convertible Preferred Stock, shares outstanding
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	1,000,000	1,000,000
Common Stock, shares issued	65,242	56,170
Common Stock, shares outstanding	65,242	56,170

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenue:
Product revenue	$ 4,601	$ 5,827	$ 8,434	$ 14,542
Service and other revenue	1,447	1,284	2,922	2,337
Grant revenue		180	270	450
Total revenue	6,048	7,291	11,626	17,329
Cost of Revenue:
Cost of product revenue	3,322	5,382	6,522	13,989
Cost of service and other revenue	1,667	1,634	3,115	3,217
Total cost of revenue	4,989	7,016	9,637	17,206
Gross profit	1,059	275	1,989	123
Operating Expense:
Research and development	11,682	11,272	23,665	23,345
Sales, general and administrative	9,374	11,558	18,928	26,843
Total operating expense	21,056	22,830	42,593	50,188
Operating loss	(19,997)	(22,555)	(40,604)	(50,065)
Interest expense	(673)	(69)	(1,098)	(139)
Other income, net	199	137	127	137
Net loss	(20,471)	(22,487)	(41,575)	(50,067)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	(13)	(60)	(32)	18
Comprehensive loss	$ (20,484)	$ (22,547)	$ (41,607)	$ (50,049)
Net loss per share:
Basic and diluted net loss per share	$ (0.33)	$ (0.40)	$ (0.70)	$ (0.90)
Shares used in computing basic and diluted net loss per share	61,922	55,658	59,660	55,433

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities
Net loss	$ (41,575)	$ (50,067)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	2,897	3,353
Amortization of debt discount and financing costs	248
Stock-based compensation	5,190	4,770
Other items	(73)	53
Changes in assets and liabilities
Accounts receivable	(1,282)	1,186
Inventory	(293)	4,082
Prepaid expenses and other assets	1,229	800
Accounts payable	(384)	(681)
Accrued expenses and other current liabilities	746	(3,719)
Deferred revenue	(97)	(204)
Lease incentives and other long-term liabilities	(588)	(523)
Net cash used in operating activities	(33,982)	(40,950)
Cash flows from investing activities
Purchases of property and equipment	(577)	(781)
Purchases of investments	(111,524)	(54,359)
Sales of investments		4,856
Maturities of investments	99,373	63,972
Net cash provided by (used in) investing activities	(12,728)	13,688
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	21,237	2,020
Proceeds from issuance of debt facility, net of issuance costs	19,766
Net cash provided by financing activities	41,003	2,020
Net decrease in cash and cash equivalents	(5,707)	(25,242)
Cash and cash equivalents at beginning of period	46,540	58,865
Cash and cash equivalents at end of period	$ 40,833	$ 33,623

Overview	6 Months Ended
Overview	Jun. 30, 2013
Accounting Policies [Abstract]
Overview	1. Overview Pacific Biosciences of California, Inc., (“Pacific Biosciences”, the “Company”, “we”, “us”) has commercialized the PacBio RS High Resolution Genetic Analyzer and the PacBio RS II Sequencing System to help scientists solve genetically complex problems. Based on our novel Single Molecule, Real-Time (SMRT) technology, our products enable scientists to increase their understanding of biological systems through targeted sequencing and insight into genetic variations. The names “Pacific Biosciences,” “PacBio,” “SMRT,” “SMRTbell” and our logo are our trademarks.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements (“financial statements”) of Pacific Biosciences of California, Inc. and its wholly-owned subsidiaries have been prepared on a consistent basis with the December 31, 2012 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. Certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to the current year’s presentation. The financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, omit certain information and footnote disclosures necessary to present the statements in accordance with U.S. generally accepted accounting principles (“GAAP”). These financial statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, which was filed on March 15, 2013. The results of operations for the first six months of fiscal 2013 are not necessarily indicative of the results to be expected for the entire fiscal year or any future periods.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting periods. Our estimates include, but are not limited to, useful lives assigned to long-lived assets, assumptions used in computing stock-based compensation expense and valuing warrants, assumptions used to value the financing derivative and long-term notes, provisions for income taxes, inventory, and contingencies. Actual results could differ from our estimates, and such differences could be material to our financial position and results of operations.

Fair Value of Financial Instruments

Assets and Liabilities measured at fair value on a recurring basis

The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of June 30, 2013 and December 31, 2012, respectively:


(in thousands)	June 30, 2013								December 31, 2012
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets
Cash and cash equivalents:
Cash and money market funds	$	20,037	$	—	$	—	$	20,037	$	11,847	$	—	$	—	$	11,847
Commercial paper		—		20,796		—		20,796		—		34,693		—		34,693

Total cash and cash equivalents		20,037		20,796		—		40,833		11,847		34,693		—		46,540

Investments:
Commercial paper		—		58,094		—		58,094		—		28,866		—		28,866
Corporate debt securities		—		1,641		—		1,641		—		13,203		—		13,203
Asset backed securities		—		6,400		—		6,400		—		955		—		955
Certificates of deposits		—		—		—		—		—		2,008		—		2,008
U.S. government and agency securities		—		—		—		—		—		9,008		—		9,008

Total investments		—		66,135		—		66,135		—		54,040		—		54,040

Total assets measured at fair value	$	20,037	$	86,931	$	—	$	106,968	$	11,847	$	88,733	$	—	$	100,580

Liabilities
Financing derivative	$	—	$	—	$	894	$	—	$	—	$	—	$	—	$	—

Total liabilities measured at fair value	$	—	$	—	$	894	$	—	$	—	$	—	$	—	$	—

All of our cash deposits and money market funds are classified within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. Our investments are classified as Level 2 instruments based on market pricing and other observable inputs. None of our investments are classified within Level 3 of the fair value hierarchy.

During the six-month periods ended June 30, 2013 and 2012, realized gains and losses on the sale of investments were immaterial and there were no material impairments of our investments.

The fair value of the Financing Derivative (as defined in Note 6. Debt Facility) liability resulting from the debt facility we entered into during the first quarter of 2013 was determined using Level 3 inputs, or significant unobservable inputs. Refer to Note 6. Debt Facility for a detailed description and valuation approach. The following table provides the changes in the fair value of the Financial Derivative during the six-month period ended June 30, 2013 (in thousands):


Financial Derivative	Amount
Balance as of December 31, 2012	$	—
Value at issuance		967
Loss on change in fair value of Financing Derivative		(73	)

Balance as of June 30, 2013	$	894

For the six-month period ended June 30, 2013 there were no assets or liabilities transferred between Level 1, Level 2, Level 3 reported at fair value on a recurring basis and valuation techniques did not change compared to the prior quarter.

Financial Assets and Liabilities not measured at fair value on a recurring basis

The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities, are determined to approximate fair value due to their short maturities. The carrying value of our facility financing obligation approximates fair value due to the time to maturity and prevailing market rates.

We determined the fair value of the Notes (as defined in Note 6. Debt Facility) from the debt facility we entered into during the first quarter of 2013 using Level 3 inputs, or significant unobservable inputs. The value of the Notes was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using a 20.8% weighted average market yield. Refer to Note 6. Debt Facility for additional details regarding the Notes. The estimated fair value and carrying value of the Notes are as follows (in thousands):


	June 30, 2013				December 31, 2012
	Fair Value		Carrying Value		Fair Value		Carrying Value
Long-term notes payable	$	13,686	$	13,007	$	—	$	—

Net Loss Per Share

The following table presents the computation of our basic and diluted net loss per share (in thousands, except per share amounts):


	Three-Months Ended June 30,						Six-Months Ended June 30,
	2013			2012			2013			2012
Net loss per share
Numerator:
Net loss	$	(20,471	)	$	(22,487	)	$	(41,575	)	$	(50,067	)

Denominator:
Weighted average shares used in computation of basic and diluted net loss per share		61,922			55,658			59,660			55,433

Basic and diluted net loss per share	$	(0.33	)	$	(0.40	)	$	(0.70	)	$	(0.90	)

The following were excluded from the computation of our diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:


(in thousands)	As of June 30,
(in thousands)	2013		2012
Options outstanding		13,696		11,976
Warrants to purchase common stock		5,504		10

Cash, Cash Equivalents and Investments

6 Months Ended

Jun. 30, 2013

Cash And Cash Equivalents [Abstract]

Cash, Cash Equivalents and Investments

3. Cash, Cash Equivalents and Investments

The following table summarizes our investments as of June 30, 2013 and December 31, 2012 (in thousands):


	As of June 30, 2013
	Amortized Cost		Gross unrealized gains		Gross unrealized losses			Fair Value
Cash and cash equivalents:
Cash and money market funds	$	20,037	$	—	$	—		$	20,037
Commercial paper		20,795		1		—			20,796

Total cash and cash equivalents		40,832		1		—			40,833

Investments:
Commercial paper		58,086		9		(1	)		58,094
Corporate debt securities		1,642		—		(1	)		1,641
Asset backed securities		6,410		—		(10	)		6,400
U.S. government and agency securities		—		—		—			—

Total investments		66,138		9		(12	)		66,135

Total cash, cash equivalents and investments	$	106,970	$	10	$	(12	)	$	106,968


	As of December 31, 2012
	Amortized Cost		Gross unrealized gains		Gross unrealized losses		Fair Value
Cash and cash equivalents:
Cash and money market funds	$	11,847	$	—	$	—	$	11,847
Commercial paper		34,690		3		—		34,693

Total cash and cash equivalents		46,537		3		—		46,540

Investments:
Commercial paper		28,859		7		—		28,866
Corporate debt securities		13,190		13		—		13,203
Asset backed securities		954		1		—		955
Certificates of deposit		2,005		3		—		2,008
U.S. government and agency securities		9,005		3		—		9,008

Total investments		54,013		27		—		54,040

Total cash, cash equivalents and investments	$	100,550	$	30	$	—	$	100,580

The estimated fair value of marketable debt securities (corporate debt securities, asset backed securities, U.S. government and agency securities, and commercial paper) as of June 30, 2013, by contractual maturity, are as follows:


(in thousands)	Fair Value
Due in one year or less	$	80,531
Due after one year through 5 years		6,400

Total investments in debt securities	$	86,931

Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.

Balance Sheet Components

6 Months Ended

Jun. 30, 2013

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Balance Sheet Components

4. Balance Sheet Components

As of June 30, 2013 and December 31, 2012 our inventory, net, consisted of the following components:


(in thousands)	June 30, 2013		December 31, 2012
Purchased materials, net	$	2,953	$	3,823
Work in process, net		5,179		3,494
Finished goods, net		2,151		2,275

Inventory, net	$	10,283	$	9,592

Contingencies	6 Months Ended
Contingencies	Jun. 30, 2013
Commitments And Contingencies Disclosure [Abstract]
Contingencies	5. Contingencies We become subject to claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Three putative class action lawsuits were filed against us and certain of our officers and directors in the Superior Court of the State of California, County of San Mateo. These actions were brought on behalf of all persons or entities that purchased or otherwise acquired our common stock pursuant or traceable to our initial public offering (“IPO”) of common stock in October 2010. The claims were initiated between October 2011 and April 2012 and have since been consolidated as In re Pacific Biosciences of California Inc. S’holder Litig., Case No. CIV509210 (the “State Court Action”). The plaintiffs in the State Court Action allege violations of several provisions of the federal securities laws in connection with our August 16, 2010 registration statement (effective, as amended, on October 26, 2010) and seek, among other things, compensatory damages, rescission, and attorneys’ fees and costs on behalf of the putative class. On October 26, 2012, the plaintiffs in the State Court Action filed a First Amended Consolidated Class Action Complaint, which the defendants answered on November 13, 2012. On June 3, 2013, the Superior Court preliminarily approved the terms of a tentative settlement reached by the parties to the State Court Action and conditionally certified the settlement class proposed by the parties, such class consisting of all persons or entities that purchased our common stock between October 27, 2010 and September 20, 2011 (inclusive). The Superior Court scheduled a hearing regarding final approval of the tentative settlement for October 25, 2013. As of June 30, 2013, we have accrued for our best estimate to resolve this matter. On December 21, 2011, we and certain of our officers and directors were named in a putative class action lawsuit filed in United States District Court for the Northern District of California (Primo v. Pacific Biosciences of California, Inc., et al., Case No. 4:11-CV-06599). On April 11, 2012, an amended complaint was filed in the Primo action, which added another plaintiff, Evan Powell. As amended, the complaint alleges violations of several provisions of the federal securities laws in connection with our August 16, 2010 registration statement (effective, as amended, on October 26, 2010), and by us and/or our employees during the class period. The complaint seeks, among other things, compensatory damages, rescission, and attorneys’ fees and costs on behalf of the putative class. On April 15, 2013, the District Court granted the defendants’ motion to dismiss the amended complaint while permitting plaintiffs to file an amended complaint within sixty days. On June 14, 2013, plaintiffs in the Primo action filed a second amended complaint. On June 13, 2013, the defendants moved to stay all proceedings in the Primo action, pending a consideration by the Superior Court of the State of California, County of San Mateo, of whether to grant final approval to the tentative settlement preliminarily approved in the State Action. The District Court has scheduled a hearing on the defendants’ motion to stay the Primo action for August 22, 2013. Pursuant to the parties’ stipulation and as ordered by the District Court, the defendants are not obligated to respond to the second amended complaint until thirty days after the District Court has ruled on the pending motion to stay and then only in the event the District Court denies the motion. On December 29, 2011, we were named as a nominal defendant, along with certain of our directors as individual defendants, in a purported shareholder derivative lawsuit filed in United States District Court for the Northern District of California (Burlingame v. Martin et al., Case No. 4:11-CV-06703). The plaintiff in the Burlingame action has agreed to dismiss the litigation in its entirety. Accordingly, by stipulation of the parties, the Burlingame action was dismissed without prejudice on April 12, 2013. We believe that the allegations in each of these pending actions are without merit and intend to vigorously contest the actions. However, there can be no assurance that we will be successful in our defense. In addition, from time to time, we are a party to litigation and subject to claims incident to the ordinary course of business. We cannot determine the ultimate outcome of these lawsuits. Except as noted above regarding the tentative settlement of the State Court Action, we cannot provide an estimate of the possible loss or possible range of loss associated with the resolution of these contingencies with certainty or confidence; therefore, except as noted above, we have not provided an estimate and we have not recorded a liability. Indemnification Pursuant to Delaware law and agreements entered into with each of our directors and certain officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and certain officers against losses suffered or incurred by the indemnified party in connection with their service to the Company, and judgments, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and certain officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fund raising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and the Company in connection with such fund raising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded at June 30, 2013.

- Definition

The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

+ Details

Debt Facility

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Debt Facility

6. Debt Facility

On February 5, 2013, we entered into a Facility Agreement (the “Facility Agreement”) with entities affiliated with Deerfield Management Company, L.P. (collectively, “Deerfield”), pursuant to which Deerfield agreed to provide $20.5 million in funding to us (the “Facility”). Under the terms of the Facility Agreement, we issued to Deerfield promissory notes in the aggregate principal amount of $20.5 million (the “Notes”). The Notes bear simple interest at a rate of 8.75% per annum, payable quarterly in arrears commencing on April 1, 2013 and on the first business day of each January, April, July and October thereafter. We received net proceeds of $20.0 million, representing $20.5 million of gross proceeds, less a $500,000 facility fee, before deducting other expenses of the transaction.

The Facility Agreement has a maximum term of seven years from inception; however it provides for the early repayment of principal in the event we have net sales (as defined in the Facility Agreement) of less than $41.0 million for the twelve-month period from the beginning of the second calendar quarter of 2014 through the first calendar quarter of 2015 (the “Milestone”). If the Milestone is not achieved, at Deerfield’s option, one-third of the original principal balance of the Facility will become due, on each of the third, fourth and fifth anniversaries of the date of the Facility Agreement.

From and after the date of the Facility Agreement, at the election of the holders of Notes representing a majority of the aggregate principal amount of the outstanding Notes, we shall apply 25% of the net proceeds from any financing that includes an equity component, including without limitation, the sale or issuance of our common stock, options, warrants or other securities convertible or exchangeable for shares of our common stock, to the payment of the Notes. This right is subject to certain exceptions set forth in the Facility Agreement, including that the right will not apply until we have issued 15.0 million shares (as adjusted for any stock split or reverse stock split) of our common stock or rights to acquire our capital stock following the date of the Facility Agreement.

Deerfield has the option to require us to repay the Notes if we complete a Major Transaction (as defined in the Facility Agreement), including a change of control or a sale of all or substantially all of our assets. Additionally, the principal balance of the Facility may become immediately due and payable upon an Event of Default (as defined in the Facility Agreement), in which case Deerfield would have the right to require us to repay 100% of the principal amount of the loan, plus any accrued and unpaid interest thereon. The Facility Agreement does not provide for a prepayment of the Notes at our option.

The Facility Agreement also contains various representations and warranties, and affirmative and negative covenants, customary for financings of this type, including restrictions on the ability of the Company and its subsidiaries to incur additional indebtedness or liens on its assets, except as permitted under the Facility Agreement. In addition, we are required to maintain consolidated cash and cash equivalents on the last day of each calendar quarter of not less than $2.0 million. As security for our repayment of our obligations under the Facility Agreement, we granted to Deerfield a security interest in substantially all of our property and interests in property.

Financing Derivative

A number of features embedded in the Notes to the Facility Agreement required accounting for as a derivative, including the indemnification of certain withholding taxes and the acceleration of debt upon (a) a qualified financing, (b) an Event of Default, (c) a Major Transaction, and (d) the exercise of the Warrant via offset to debt principal. These features represent a single derivative (the “Financing Derivative”) that was bifurcated from the debt instrument and accounted for as a liability at fair value, with changes in fair value between reporting periods recorded in other income (expense), net. The fair value of the Financing Derivative as of February 5, 2013 and June 30, 2013, was $1.0 million and $0.9 million, respectively.

The value of the Financing Derivative as of February 5, 2013 and June 30, 2013 was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using a 20.8% weighted average market yield.

Warrants

In connection with the execution of the Facility Agreement, on February 5, 2013, we issued to Deerfield warrants to purchase an aggregate of 5,500,000 shares of common stock immediately exercisable at an exercise price per share initially equal to $2.63 (the “Warrants”). The number of shares of common stock into which the Warrants are exercisable and the exercise price will be adjusted to reflect any stock splits, payment of stock dividends, recapitalizations, reclassifications or other similar adjustments in the number of outstanding shares of common stock. The exercise price may also be adjusted to reflect certain dividends or other distributions, including distributions of stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or similar transaction.

The Warrants are classified within additional paid-in capital and reported at their grant date fair value on February 5, 2013 of $6.4 million. We estimated the fair value of the Warrants using the Black-Scholes option pricing model using the following assumptions:


Expected term	7 years
Expected volatility	50	%
Risk-free interest rate	1.4	%
Dividend yield	—

Notes

The Notes and Warrants were initially recorded at a value of $14.1 million and $6.4 million, respectively, based upon the relative fair value allocation of the $20.5 million of proceeds. Additionally, facility fees and other issuance costs were allocated based on the relative fair value of the Facility and the Warrants. The amount allocated to the Notes was then reduced by the $1.0 million fair value of the Financing Derivative, such that the Financing Derivative was recorded at its absolute fair value. As a result, the carrying value of the Notes at the inception of the debt was $12.8 million, resulting in an original issue discount of $7.7 million. The discount will be accreted to the $20.5 million face value of the Notes over the expected maturity period of seven years using the effective interest method, with an effective interest rate of 20.6%.

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2013
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity Stock Offering During April 2012, we filed a shelf registration statement on Form S-3 with the SEC pursuant to which we may, from time to time, sell up to an aggregate of $150.0 million of our common stock, warrants or debt securities. On May 1, 2012, the registration statement was declared effective by the SEC. On October 5, 2012, we entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), pursuant to which we may offer and sell, from time to time, through Cantor, shares of our common stock having an aggregate offering price of up to $30.0 million through an “at-the-market” offering. We are not obligated to make any sales of shares under the Sales Agreement. We pay Cantor a commission equal to 3.0% of the gross proceeds from the sale of shares of our common stock under the Sales Agreement and reimburse up to $50,000 of legal expenses incurred by Cantor. During the quarter ended June 30, 2013, we sold 4.4 million shares of common stock through our “at-the-market” offering at an average price of $2.66, with net proceeds of $11.3 million. As of June 30, 2013, we have sold a total of 8.3 million shares of our common stock at an average price of $2.51 through our “at-the-market” offering.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Stock Option Plans

6 Months Ended

Jun. 30, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Plans

8. Stock Option Plans

As of June 30, 2013, we had three active equity compensation plans, the 2010 Equity Incentive Plan, or 2010 Plan, the 2010 Outside Director Equity Incentive Plan, or 2010 Director Plan, and the 2010 Employee Stock Purchase Plan (the “ESPP”).

As of June 30, 2013, 786,255 shares of our common stock remain reserved for issuance under our ESPP. Our ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Each offering period generally consists of four purchase periods, each purchase period being six months. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. Shares issued under the ESPP totaled 733,111 and 428,604 shares during the six-month periods ended June 30, 2013 and 2012, respectively. We estimate the value of the employee stock purchase rights on the grant date using the Black-Scholes option pricing model.

The following table summarizes stock option activity for all stock option plans (in thousands, except per share amounts):


	Shares available for grant			Common Stock Options Outstanding
	Shares available for grant			Number of shares			Exercise price		Weighted average exercise price
Balances, December 31, 2012		2,872			12,016		$	0.20 – 16.00	$	5.37
Additional shares reserved		3,370
Options granted		(2,025	)		2,025			2.11 – 2.89		2.25
Options exercised		—			(29	)		1.83 – 2.52		1.88
Options canceled		316			(316	)		1.16 – 16.00		5.12

Balances, June 30, 2013		4,533			13,696		$	0.20 – 16.00	$	4.92

Stock-based Compensation

Total stock-based compensation expense for employee stock options and stock purchases under the ESPP, consists of the following (in thousands):


	Three-Month Periods Ended June 30,				Six-Month Periods Ended June 30,
	2013		2012		2013		2012
Cost of revenue	$	100	$	143	$	236	$	309
Research and development		1,024		1,069		2,241		2,202
Sales, general and administrative		1,320		1,371		2,713		2,259

Total stock-based compensation expense	$	2,444	$	2,583	$	5,190	$	4,770

We estimated the fair value of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards.

The fair value of the common stock underlying stock options granted through the date of our IPO, were estimated by our board of directors on the date of grant. The fair value of the shares of common stock underlying stock options has historically been the responsibility of, and determined by, our board of directors. Because there was no public market for our common stock, our board of directors determined fair value of the common stock at the time of grant by considering a number of objective and subjective factors including independent third-party valuations, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock and general and industry specific economic outlook, amongst other factors. Our common stock became publicly listed upon our IPO, from which time options granted are issued with an exercise price equal to the closing price on the date of grant.

The fair value of employee stock options was estimated using the following weighted average assumptions:


	Three-Month Periods Ended June 30,						Six-Month Periods Ended June 30,
	2013			2012			2013			2012
Expected term in years		6.1			6.1			6.1			6.1
Expected volatility		65.0	%		65.0	%		65.0	%		65.0	%
Risk-free interest rate		1.1	%		1.0	%		1.1	%		1.1	%
Dividend yield		—			—			—			—

Expected term — Expected term represents the period that our stock-based awards are expected to be outstanding. Our assumptions about the expected term have been on our historic cancellation and exercise experience and trends as well as our expectations for future periods.

Expected volatility — We do not have sufficient trading history to solely rely on the volatility of our own common stock for establishing expected volatility. Therefore, we based our expected volatility on the historical stock volatilities of our common stock as well as several comparable publicly listed companies over a period equal to the expected terms of the options.

Risk-free interest rate — The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the option’s expected term.

Expected dividend yield — We have never paid dividends and do not expect to pay dividends in the foreseeable future.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Assets and Liabilities measured at fair value on a recurring basis

The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of June 30, 2013 and December 31, 2012, respectively:


(in thousands)	June 30, 2013								December 31, 2012
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets
Cash and cash equivalents:
Cash and money market funds	$	20,037	$	—	$	—	$	20,037	$	11,847	$	—	$	—	$	11,847
Commercial paper		—		20,796		—		20,796		—		34,693		—		34,693

Total cash and cash equivalents		20,037		20,796		—		40,833		11,847		34,693		—		46,540

Investments:
Commercial paper		—		58,094		—		58,094		—		28,866		—		28,866
Corporate debt securities		—		1,641		—		1,641		—		13,203		—		13,203
Asset backed securities		—		6,400		—		6,400		—		955		—		955
Certificates of deposits		—		—		—		—		—		2,008		—		2,008
U.S. government and agency securities		—		—		—		—		—		9,008		—		9,008

Total investments		—		66,135		—		66,135		—		54,040		—		54,040

Total assets measured at fair value	$	20,037	$	86,931	$	—	$	106,968	$	11,847	$	88,733	$	—	$	100,580

Liabilities
Financing derivative	$	—	$	—	$	894	$	—	$	—	$	—	$	—	$	—

Total liabilities measured at fair value	$	—	$	—	$	894	$	—	$	—	$	—	$	—	$	—

Net Loss Per Share

Net Loss Per Share

The following table presents the computation of our basic and diluted net loss per share (in thousands, except per share amounts):


	Three-Months Ended June 30,						Six-Months Ended June 30,
	2013			2012			2013			2012
Net loss per share
Numerator:
Net loss	$	(20,471	)	$	(22,487	)	$	(41,575	)	$	(50,067	)

Denominator:
Weighted average shares used in computation of basic and diluted net loss per share		61,922			55,658			59,660			55,433

Basic and diluted net loss per share	$	(0.33	)	$	(0.40	)	$	(0.70	)	$	(0.90	)

The following were excluded from the computation of our diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:


(in thousands)	As of June 30,
(in thousands)	2013		2012
Options outstanding		13,696		11,976
Warrants to purchase common stock		5,504		10

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Summary of Assets and Liabilities Measured at Fair Value Classified Based on Level of Input

The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of June 30, 2013 and December 31, 2012, respectively:


(in thousands)	June 30, 2013								December 31, 2012
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets
Cash and cash equivalents:
Cash and money market funds	$	20,037	$	—	$	—	$	20,037	$	11,847	$	—	$	—	$	11,847
Commercial paper		—		20,796		—		20,796		—		34,693		—		34,693

Total cash and cash equivalents		20,037		20,796		—		40,833		11,847		34,693		—		46,540

Investments:
Commercial paper		—		58,094		—		58,094		—		28,866		—		28,866
Corporate debt securities		—		1,641		—		1,641		—		13,203		—		13,203
Asset backed securities		—		6,400		—		6,400		—		955		—		955
Certificates of deposits		—		—		—		—		—		2,008		—		2,008
U.S. government and agency securities		—		—		—		—		—		9,008		—		9,008

Total investments		—		66,135		—		66,135		—		54,040		—		54,040

Total assets measured at fair value	$	20,037	$	86,931	$	—	$	106,968	$	11,847	$	88,733	$	—	$	100,580

Liabilities
Financing derivative	$	—	$	—	$	894	$	—	$	—	$	—	$	—	$	—

Total liabilities measured at fair value	$	—	$	—	$	894	$	—	$	—	$	—	$	—	$	—

Changes in Fair Value of Financial Derivative

The following table provides the changes in the fair value of the Financial Derivative during the six-month period ended June 30, 2013 (in thousands):


Financial Derivative	Amount
Balance as of December 31, 2012	$	—
Value at issuance		967
Loss on change in fair value of Financing Derivative		(73	)

Balance as of June 30, 2013	$	894

Estimated Fair Value and Carrying Value of Notes

The estimated fair value and carrying value of the Notes are as follows (in thousands):


	June 30, 2013				December 31, 2012
	Fair Value		Carrying Value		Fair Value		Carrying Value
Long-term notes payable	$	13,686	$	13,007	$	—	$	—

Computation of Basic and Diluted Net Loss Per Share

The following table presents the computation of our basic and diluted net loss per share (in thousands, except per share amounts):


	Three-Months Ended June 30,						Six-Months Ended June 30,
	2013			2012			2013			2012
Net loss per share
Numerator:
Net loss	$	(20,471	)	$	(22,487	)	$	(41,575	)	$	(50,067	)

Denominator:
Weighted average shares used in computation of basic and diluted net loss per share		61,922			55,658			59,660			55,433

Basic and diluted net loss per share	$	(0.33	)	$	(0.40	)	$	(0.70	)	$	(0.90	)

Anti-dilutive Excluded from Computation of Diluted Net Loss Per Share

The following were excluded from the computation of our diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:


(in thousands)	As of June 30,
(in thousands)	2013		2012
Options outstanding		13,696		11,976
Warrants to purchase common stock		5,504		10

Cash, Cash Equivalents and Investments (Tables)

6 Months Ended

Jun. 30, 2013

Cash And Cash Equivalents [Abstract]

Summary of Cash and Cash Equivalents and Investments

The following table summarizes our investments as of June 30, 2013 and December 31, 2012 (in thousands):


	As of June 30, 2013
	Amortized Cost		Gross unrealized gains		Gross unrealized losses			Fair Value
Cash and cash equivalents:
Cash and money market funds	$	20,037	$	—	$	—		$	20,037
Commercial paper		20,795		1		—			20,796

Total cash and cash equivalents		40,832		1		—			40,833

Investments:
Commercial paper		58,086		9		(1	)		58,094
Corporate debt securities		1,642		—		(1	)		1,641
Asset backed securities		6,410		—		(10	)		6,400
U.S. government and agency securities		—		—		—			—

Total investments		66,138		9		(12	)		66,135

Total cash, cash equivalents and investments	$	106,970	$	10	$	(12	)	$	106,968


	As of December 31, 2012
	Amortized Cost		Gross unrealized gains		Gross unrealized losses		Fair Value
Cash and cash equivalents:
Cash and money market funds	$	11,847	$	—	$	—	$	11,847
Commercial paper		34,690		3		—		34,693

Total cash and cash equivalents		46,537		3		—		46,540

Investments:
Commercial paper		28,859		7		—		28,866
Corporate debt securities		13,190		13		—		13,203
Asset backed securities		954		1		—		955
Certificates of deposit		2,005		3		—		2,008
U.S. government and agency securities		9,005		3		—		9,008

Total investments		54,013		27		—		54,040

Total cash, cash equivalents and investments	$	100,550	$	30	$	—	$	100,580

Estimated Fair Value of Marketable Debt Securities


(in thousands)	Fair Value
Due in one year or less	$	80,531
Due after one year through 5 years		6,400

Total investments in debt securities	$	86,931

Balance Sheet Components (Tables)

6 Months Ended

Jun. 30, 2013

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Components of Inventory

As of June 30, 2013 and December 31, 2012 our inventory, net, consisted of the following components:


(in thousands)	June 30, 2013		December 31, 2012
Purchased materials, net	$	2,953	$	3,823
Work in process, net		5,179		3,494
Finished goods, net		2,151		2,275

Inventory, net	$	10,283	$	9,592

Debt Facility (Tables)

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Fair Value of Warrants

We estimated the fair value of the Warrants using the Black-Scholes option pricing model using the following assumptions:


Expected term	7 years
Expected volatility	50	%
Risk-free interest rate	1.4	%
Dividend yield	—

Stock Option Plans (Tables)

6 Months Ended

Jun. 30, 2013

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Option Activity

The following table summarizes stock option activity for all stock option plans (in thousands, except per share amounts):


	Shares available for grant			Common Stock Options Outstanding
	Shares available for grant			Number of shares			Exercise price		Weighted average exercise price
Balances, December 31, 2012		2,872			12,016		$	0.20 – 16.00	$	5.37
Additional shares reserved		3,370
Options granted		(2,025	)		2,025			2.11 – 2.89		2.25
Options exercised		—			(29	)		1.83 – 2.52		1.88
Options canceled		316			(316	)		1.16 – 16.00		5.12

Balances, June 30, 2013		4,533			13,696		$	0.20 – 16.00	$	4.92

Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense for employee stock options and stock purchases under the ESPP, consists of the following (in thousands):


	Three-Month Periods Ended June 30,				Six-Month Periods Ended June 30,
	2013		2012		2013		2012
Cost of revenue	$	100	$	143	$	236	$	309
Research and development		1,024		1,069		2,241		2,202
Sales, general and administrative		1,320		1,371		2,713		2,259

Total stock-based compensation expense	$	2,444	$	2,583	$	5,190	$	4,770

Schedule of Fair Value of Employee Stock Options

The fair value of employee stock options was estimated using the following weighted average assumptions:


	Three-Month Periods Ended June 30,						Six-Month Periods Ended June 30,
	2013			2012			2013			2012
Expected term in years		6.1			6.1			6.1			6.1
Expected volatility		65.0	%		65.0	%		65.0	%		65.0	%
Risk-free interest rate		1.1	%		1.0	%		1.1	%		1.1	%
Dividend yield		—			—			—			—

Summary of Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value Classified Based on Level of Input (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Assets
Total assets measured at fair value	$ 106,968	$ 100,580
Liabilities
Total liabilities measured at fair value
Financing derivative [Member]
Liabilities
Total liabilities measured at fair value
Cash and cash equivalents [Member]
Assets
Total cash and cash equivalents	40,833	46,540
Cash and cash equivalents [Member] \| Cash and money market funds [Member]
Assets
Total cash and cash equivalents	20,037	11,847
Cash and cash equivalents [Member] \| Commercial paper [Member]
Assets
Total cash and cash equivalents	20,796	34,693
Investments [Member]
Assets
Total investments	66,135	54,040
Investments [Member] \| Commercial paper [Member]
Assets
Total investments	58,094	28,866
Investments [Member] \| Corporate debt securities [Member]
Assets
Total investments	1,641	13,203
Investments [Member] \| Asset backed securities [Member]
Assets
Total investments	6,400	955
Investments [Member] \| Certificates of deposits [Member]
Assets
Total investments		2,008
Investments [Member] \| U.S. government and agency securities [Member]
Assets
Total investments		9,008
Level 1 [Member]
Assets
Total assets measured at fair value	20,037	11,847
Liabilities
Total liabilities measured at fair value
Level 1 [Member] \| Financing derivative [Member]
Liabilities
Total liabilities measured at fair value
Level 1 [Member] \| Cash and cash equivalents [Member]
Assets
Total cash and cash equivalents	20,037	11,847
Level 1 [Member] \| Cash and cash equivalents [Member] \| Cash and money market funds [Member]
Assets
Total cash and cash equivalents	20,037	11,847
Level 1 [Member] \| Cash and cash equivalents [Member] \| Commercial paper [Member]
Assets
Total cash and cash equivalents
Level 1 [Member] \| Investments [Member]
Assets
Total investments
Level 1 [Member] \| Investments [Member] \| Commercial paper [Member]
Assets
Total investments
Level 1 [Member] \| Investments [Member] \| Corporate debt securities [Member]
Assets
Total investments
Level 1 [Member] \| Investments [Member] \| Asset backed securities [Member]
Assets
Total investments
Level 1 [Member] \| Investments [Member] \| Certificates of deposits [Member]
Assets
Total investments
Level 1 [Member] \| Investments [Member] \| U.S. government and agency securities [Member]
Assets
Total investments
Level 2 [Member]
Assets
Total assets measured at fair value	86,931	88,733
Liabilities
Total liabilities measured at fair value
Level 2 [Member] \| Financing derivative [Member]
Liabilities
Total liabilities measured at fair value
Level 2 [Member] \| Cash and cash equivalents [Member]
Assets
Total cash and cash equivalents	20,796	34,693
Level 2 [Member] \| Cash and cash equivalents [Member] \| Cash and money market funds [Member]
Assets
Total cash and cash equivalents
Level 2 [Member] \| Cash and cash equivalents [Member] \| Commercial paper [Member]
Assets
Total cash and cash equivalents	20,796	34,693
Level 2 [Member] \| Investments [Member]
Assets
Total investments	66,135	54,040
Level 2 [Member] \| Investments [Member] \| Commercial paper [Member]
Assets
Total investments	58,094	28,866
Level 2 [Member] \| Investments [Member] \| Corporate debt securities [Member]
Assets
Total investments	1,641	13,203
Level 2 [Member] \| Investments [Member] \| Asset backed securities [Member]
Assets
Total investments	6,400	955
Level 2 [Member] \| Investments [Member] \| Certificates of deposits [Member]
Assets
Total investments		2,008
Level 2 [Member] \| Investments [Member] \| U.S. government and agency securities [Member]
Assets
Total investments		$ 9,008
Level 3 [Member]
Assets
Total assets measured at fair value
Liabilities
Total liabilities measured at fair value	894
Level 3 [Member] \| Financing derivative [Member]
Liabilities
Total liabilities measured at fair value	894
Level 3 [Member] \| Cash and cash equivalents [Member]
Assets
Total cash and cash equivalents
Level 3 [Member] \| Cash and cash equivalents [Member] \| Cash and money market funds [Member]
Assets
Total cash and cash equivalents
Level 3 [Member] \| Cash and cash equivalents [Member] \| Commercial paper [Member]
Assets
Total cash and cash equivalents
Level 3 [Member] \| Investments [Member]
Assets
Total investments
Level 3 [Member] \| Investments [Member] \| Commercial paper [Member]
Assets
Total investments
Level 3 [Member] \| Investments [Member] \| Corporate debt securities [Member]
Assets
Total investments
Level 3 [Member] \| Investments [Member] \| Asset backed securities [Member]
Assets
Total investments
Level 3 [Member] \| Investments [Member] \| Certificates of deposits [Member]
Assets
Total investments
Level 3 [Member] \| Investments [Member] \| U.S. government and agency securities [Member]
Assets
Total investments

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Feb. 05, 2013
Accounting Policies [Abstract]
Impairment charges on investments	$ 0	$ 0
Fair value assets liabilities transfer between levels	$ 0
Future cash flows weighted average market yield			20.80%

Summary of Significant Accounting Policies - Changes in Fair Value of Financial Derivative (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2013 USD ($)
Accounting Policies [Abstract]
Beginning Balance
Value at issuance	967
Loss on change in fair value of Financing Derivative	(73)
Ending Balance	$ 894

Summary of Significant Accounting Policies - Estimated Fair Value and Carrying Value of Notes (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Feb. 05, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term notes payable	$ 13,007	$ 12,800
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term notes payable	13,686
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term notes payable	$ 13,007

Summary of Significant Accounting Policies - Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Numerator:
Net loss	$ (20,471)	$ (22,487)	$ (41,575)	$ (50,067)
Denominator:
Weighted average shares used in computation of basic and diluted net loss per share	61,922	55,658	59,660	55,433
Basic and diluted net loss per share	$ (0.33)	$ (0.40)	$ (0.70)	$ (0.90)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Summary of Significant Accounting Policies - Anti-dilutive Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Options outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock excluded from the computation of diluted net loss per share	13,696	11,976
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock excluded from the computation of diluted net loss per share	5,504	10

Cash, Cash Equivalents and Investments - Summary of Cash and Cash Equivalents and Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 106,970	$ 100,550
Gross unrealized gains	10	30
Gross unrealized losses	(12)
Fair Value	106,968	100,580
Cash and cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	40,832	46,537
Gross unrealized gains	1	3
Gross unrealized losses
Fair Value	40,833	46,540
Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	66,138	54,013
Gross unrealized gains	9	27
Gross unrealized losses	(12)
Fair Value	66,135	54,040
Cash and money market funds [Member] \| Cash and cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	20,037	11,847
Gross unrealized gains
Gross unrealized losses
Fair Value	20,037	11,847
Commercial paper [Member] \| Cash and cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	20,795	34,690
Gross unrealized gains	1	3
Gross unrealized losses
Fair Value	20,796	34,693
Commercial paper [Member] \| Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	58,086	28,859
Gross unrealized gains	9	7
Gross unrealized losses	(1)
Fair Value	58,094	28,866
Corporate debt securities [Member] \| Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,642	13,190
Gross unrealized gains		13
Gross unrealized losses	(1)
Fair Value	1,641	13,203
Asset backed securities [Member] \| Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	6,410	954
Gross unrealized gains		1
Gross unrealized losses	(10)
Fair Value	6,400	955
U.S. government and agency securities [Member] \| Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		9,005
Gross unrealized gains		3
Gross unrealized losses
Fair Value		9,008
Certificates of deposits [Member] \| Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		2,005
Gross unrealized gains		3
Gross unrealized losses
Fair Value		$ 2,008

Cash, Cash Equivalents and Investments - Estimated Fair Value of Marketable Debt Securities (Detail) $ in Thousands	Jun. 30, 2013 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Total investments in debt securities	$ 86,931
Due in one year or less [Member]
Schedule of Available-for-sale Securities [Line Items]
Total investments in debt securities	80,531
Due after one year through 5 years [Member]
Schedule of Available-for-sale Securities [Line Items]
Total investments in debt securities	$ 6,400

Balance Sheet Components - Components of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Purchased materials, net	$ 2,953	$ 3,823
Work in process, net	5,179	3,494
Finished goods, net	2,151	2,275
Inventory, net	$ 10,283	$ 9,592

Contingencies - Additional Information (Detail) $ in Thousands	Jun. 30, 2013 USD ($)
Loss Contingency [Abstract]
Additional liability associated with indemnification obligations	$ 0

Debt Facility - Additional Information (Detail)	1 Months Ended	6 Months Ended
Debt Facility - Additional Information (Detail)	Feb. 05, 2013 USD ($)	Jun. 30, 2013 USD ($) $ / Warrant shares	Dec. 31, 2012 USD ($)
Line of Credit Facility [Line Items]
Principal amount of notes	$ 14,100,000
Facility Agreement period		7 years
Principal early repayments maximum requirement of net sales amount		$ 41,000,000
Facility Due Dates		On each of the third, fourth and fifth anniversaries of the date of the Facility Agreement.
Percentage of net proceeds from out side financing or equity component		25.00%
Facility agreement exercisable limit \| shares		15,000,000
Percentage of principal amount repaid		100.00%
Cash and cash equivalent minimum amount quarterly required		$ 2,000,000
Fair value of the Financing Derivative	$ 967,000	$ 894,000
Weighted average market yield of derivative	20.80%	20.80%
Purchase shares of common stock \| shares		5,500,000
Common stock aggregate exercise price \| $ / Warrant		2.63
Fair value of the warrants	$ 6,400,000
Allocation of notes calculated on a relative fair value basis		$ 20,500,000
Notes recorded	$ 12,800,000	13,007,000
Additional discount allocated to the warrants		$ 7,700,000
Expected maturity period		7 years
Effective interest rate		20.60%
Deerfield promissory notes [Member]
Line of Credit Facility [Line Items]
Principal amount of notes		$ 20,500,000
Deerfield promissory notes simple interest		8.75%
Facility fee		$ 20,000,000
Net proceeds of payable quarterly arrears		$ 500,000

Debt Facility - Fair Value of Warrants (Detail)	6 Months Ended
Debt Facility - Fair Value of Warrants (Detail)	Jun. 30, 2013
Debt Disclosure [Abstract]
Expected term	7 years
Expected volatility	50.00%
Risk-free interest rate	1.40%
Dividend yield

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2012	Oct. 05, 2012	Apr. 30, 2012
Equity [Line Items]
Common stock, warrants or debt securities					$ 150,000,000
Commission to Cantor		3.00%
Total proceeds from issuance of Common stock, net of issuance costs		$ 21,237,000	$ 2,020,000
Cantor [Member]
Equity [Line Items]
Common stock offering price Cantor shares				$ 30,000,000
Legal expenses incurred by Cantor		$ 50,000
At the Market Offering [Member]
Equity [Line Items]
Shares issued	4.4	8.3
Average common stock price per share	$ 2.66	$ 2.51
At the Market Offering Net [Member]
Equity [Line Items]
Total proceeds from issuance of Common stock, net of issuance costs	$ 11,300,000

Stock Option Plans - Additional Information (Detail)	6 Months Ended
Stock Option Plans - Additional Information (Detail)	Jun. 30, 2013 PurchasePeriod CompensationPlan shares	Jun. 30, 2012 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity compensation plans \| CompensationPlan	3
Number of purchase periods \| PurchasePeriod	4
Purchase period of ESPP	6 months
Percentage of fair market value at which stock can be purchased	85.00%
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance	786,255
Shares issued under the ESPP	733,111	428,604

Stock Option Plans - Summary of Stock Option Activity (Detail) - $ / shares shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balances, December 31, 2012, Number of shares	12,016
Options granted, Number of shares	2,025
Options exercised, Number of shares	(29)
Options canceled, Number of shares	(316)
Balances, June 30, 2013, Number of shares	13,696	12,016
Balances, December, 31, 2012, Weighted average exercise price per share	$ 5.37
Options granted, Weighted average exercise price per share	2.25
Options exercised, Weighted average exercise price per share	1.88
Options canceled, Weighted average exercise price per share	5.12
Balances June, 30, 2013, Weighted average exercise price per share	$ 4.92	$ 5.37
Equity Option [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balances, December 31, 2012, Shares available for grant	2,872
Additional shares reserved, Shares available for grant	3,370
Options granted, Shares available for grant	(2,025)
Options exercised, Shares available for grant
Options canceled, Shares available for grant	316
Balances, June 30, 2013, Shares available for grant	4,533	2,872
0.20 - 16.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower range	$ 0.20	$ 0.20
Exercise price, upper range	16.00	$ 16.00
2.11 - 2.89 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower range	2.11
Exercise price, upper range	2.89
1.83 - 2.52 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower range	1.83
Exercise price, upper range	2.52
1.16 - 16.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower range	1.16
Exercise price, upper range	$ 16.00

Stock Option Plans - Schedule of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 2,444	$ 2,583	$ 5,190	$ 4,770
Cost of revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	100	143	236	309
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	1,024	1,069	2,241	2,202
Sales, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 1,320	$ 1,371	$ 2,713	$ 2,259

Stock Option Plans - Schedule of Fair Value of Employee Stock Options (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Share Based Compensation [Abstract]
Expected term in years	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days
Expected volatility	65.00%	65.00%	65.00%	65.00%
Risk-free interest rate	1.10%	1.00%	1.10%	1.10%
Dividend yield